The immunostaining of pre-CRT and postoperative tumor specimens was demonstrated to lead to a significant increase in CD8+ TILs after CRT, and 5-year recurrence-free survival rates were improved in this patient subpopulation (87.5% vs. 57.8%). This evidence concerns the gene CD8A and neoplasm.